NEWS: Chimeron Bio Partners with George Mason University to Develop COVID-19 Vaccine

Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders

The Latest from Chimeron Bio

In the News

May 28, 2020

Chimeron Bio and George Mason University’s National Center for Biodefense and Infectious Diseases Partner to Develop a Coronavirus (COVID-19) Vaccine using ChaESAR™ Technology

The vaccine development will be based on Chimeron Bio’s ChaESAR™ self-amplifying RNA technology and will integrate Mason’s complimenting expertise and Biomedical Research Laboratory (BRL).

From Our Blog

April 16, 2020

RNA Leads the Way for a COVID-19 Vaccine

The COVID-19 pandemic caused by SARS-CoV-2 has impacted us all severely, and the scientific community is working hard to stop the spread now and reemergence in the future. Leading the way is a next generation vaccine based on synthetic RNA biology.

Learn more about our COVID-19 Vaccine Program.

See what makes ChaESAR™ a robust anti-viral approach.

Read the Press Release